A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Seagen Inc.
University of Nebraska
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
Eisai Inc.
Yale University
M.D. Anderson Cancer Center